Low-birth weight and pre-term delivery in relation to Lopinavir/ritonavir use in pregnancy

American Journal of Infectious Diseases

Volumn 4, Issue 4, 2008, Pages 209-214

  Senise, Jorge ^a,b   Cruz, Reisson ^a   Palacios, Ricardo ^a   Bonafé, Simone ^a,b   Vaz, Maria Jose Rodrigues ^a   Lacerda, Ana Paula ^c   Ahmed, Abes ^a   Castelo, Adauto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL IPIRANGA   (Brazil)

^c Abbott Laboratórios do Brasil   (Brazil)

Author keywords

HIV mother to child transmission; Lopinavir; Low birth weight; Pre term delivery; Pregnancy

Indexed keywords

DIDANOSINE; DIDANOSINE PLUS LAMIVUDINE PLUS ZIDOVUDINE; DIDANOSINE PLUS STAVUDINE; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ECHOGRAPHY; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; MATERNAL AGE; NEWBORN; NONHUMAN; PREMATURE LABOR; RETROSPECTIVE STUDY; VIROLOGY; VIRUS TRANSMISSION;

EID: 64549112685     PISSN: 15536203     EISSN: None     Source Type: Journal    
DOI: 10.3844/ajidsp.2008.209.214     Document Type: Article

References (25)

1. Wit, F., J. Nellen and A. Bergshoeff et al., 2003. Plasma nelfinavir concentrations are significantly lower in pregnancy. Antivir. Ther., 8: S214-S215.
2. Watts, D.H., R. Balasubramanian and R.T. Maupin Jr. et al., 2004. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am. J. Obstet. Gynecol., 190: 506-516.
3. Patel, S.M., S. Johnson and S.M. Belknap et al., 2004. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J. Acquir. Immune. Defic. Syndr., 35 (2): 120-125.
4. Mazhude, C., S. Jones and S. Murad et al., 2002. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS, 16 (11): 1566-1568.
5. Knudtson, E., M. Para, H. Boswell, Fan-Havard and P. Drug Rash, 2003. Eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Obstet. Gynecol., 101 (5 Pt 2): 1094-1097.
6. Stern, J.O., P.A. Robinson and J. Love et al., 2003. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J. Acquir. Immune. Defic. Syndr., 34 (Suppl 1): S21-S33.
7. Boehringer-Ingelheim, 2005. Pharmaceuticals Inc. Viramune Drug Label.
8. Hitti, J., L.M. Frenkel and A.M. Stek et al., 2004. For the PACTG 1022 Study Team. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J. Acquir. Immune. Defic. Syndr., 36 (3): 772-776.
9. King, M.S., B.M. Bernstein and S.L. Walmsley et al., 2004. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. JID, 190: 280-284.
10. Stek, A., M. Mirochnick and E. Capparelli et al., 2004. Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026. Program and abstracts of the 15th International AIDS Conference; Bangkok, Thailand.
11. Public Health Service Task Force, 2005. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States, .
12. Hirsch, M.S., F. Brun-Vezinet and R.T. D'Aquila et al., 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA, 283 (18): 2417-2426.
13. The EuroGuidelines Group for HIV Resistance, 2001. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: Recommendations for the European setting. AIDS, 15 (3): 309-320.
14. Garcia, P.M., L.A. kalish and J. Pitt et al., 1999. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N. Engl. J. Med., 341 (6): 394-402.
15. Katzenstein, D.A., M. Mbizvo and L. Zijenah et al., 1999. Serum level of maternal human immunodeficiency virus (HIV) RNA, infant mortality and vertical transmission of HIV in Zimbabwe. J. Infect. Dis., 179 (6): 1382-1387.
16. Cooper, E.R., M. Charurat and L. Mofenson et al., 2002. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J. Acquir. Immun. Defic. Syndr., 29 (5): 484-494.
17. Walmsley, S., B. Bernstein and M. King et al., 2002. M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med., 346 (26): 2039-2046.
18. Katlama, C., M.T. Carvalho and D. Cooper et al., 2007. TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: week 24 primary analysis of POWER 1 (TMC114-C213). Program and abstracts of the 3rd International AIDS Society Conference; Rio de Janeiro, Brazil.
19. Martin, J.A., B.E. Hamilton and S.J. Ventura et al., 2002. Births: final data for 2000. National vital statistics reports. Hyattsville, Md.: National Center for Health Statistics, Vol. 50. No. 5.
20. Tuomala, R.E. and D.E. Shapiro et al., 2002. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N. Engl. J. Med., 346 (24): 1863-1870.
21. Beckerman, K.C.D. and P. Garcia et al., 2004. Association between Antiretroviral Therapy during pregnancy and prematurity/low birth weight. 11th Conference of Retroviruses and Opportunistic Infection. San Francisco.
22. Kowalska, A. and T. Niemiec et al., 2003. Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women. Med. Wieku. Rozwoj., 7 (4 Pt 1): 459-468.
23. Cotter, A.M., A.G. Garcia and M.L. Duthely et al., 2006. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight or stillbirth? J. Infect. Dis., 193 (9): 1195-1201.
24. The European Collaborative Study and the Swiss Mother+Child HIV Cohort Study, 2000. Combination antiretroviral therapy and duration of pregnancy. AIDS, 14: 2913-2920.
25. Mirochnick, M., A. Stek and A. Capparelli et al., 2006. PACTG 1026s Protocol Team. Adequate Lopinavir Exposure Achieved with a Higher Dose during the Third Trimester of Pregnancy. 13th on Retroviruses and Opportunistic Infections. Denver.